<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dosing for prolonged infusions of beta-lactams&lt;sup&gt;[1-8]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dosing for prolonged infusions of beta-lactams<sup>[1-8]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Dosing for prolonged infusions of beta-lactams<sup>[1-8]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1_left"> </td> <td class="subtitle1_left">Creatinine clearance</td> <td class="subtitle1_left">Dose</td> <td class="subtitle1_left">Dosing interval</td> <td class="subtitle1_left">Infusion time</td> </tr> <tr> <td class="subtitle2_left_white" rowspan="3">Piperacillin-tazobactam<sup>*</sup></td> <td>&gt;20 mL/minute</td> <td>3.375 or 4.5 g</td> <td>Every 8 hours</td> <td>4 hours</td> </tr> <tr> <td>≤20 mL/minute or intermittent HD or PD</td> <td>3.375 or 4.5 g</td> <td>Every 12 hours</td> <td>4 hours</td> </tr> <tr> <td>CRRT<sup>¶</sup></td> <td>3.375 or 4.5 g</td> <td>Every 8 hours</td> <td>4 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td class="subtitle2_left_white" rowspan="5">Cefepime<sup>Δ</sup></td> <td>≥50 mL/minute</td> <td>2 g</td> <td>Every 8 hours</td> <td>3 to 4 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>30 to 49 mL/minute</td> <td>2 g</td> <td>Every 12 hours</td> <td>3 to 4 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>15 to 29 mL/minute</td> <td>1 g</td> <td>Every 12 hours</td> <td>3 to 4 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>&lt;15 mL/minute or intermittent HD</td> <td>1 g</td> <td>Every 24 hours</td> <td>3 to 4 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>CRRT<sup>¶</sup></td> <td>2 g</td> <td>Every 12 hours</td> <td>3 to 4 hours</td> </tr> <tr> <td class="subtitle2_left_white" rowspan="5">Imipenem<sup>◊</sup></td> <td>&gt;70 mL/minute</td> <td>500 mg or 1 g</td> <td>Every 6 hours</td> <td>3 hours</td> </tr> <tr> <td>41 to 70 mL/minute</td> <td>500 mg or 750 mg</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr> <td>21 to 40 mL/minute</td> <td>250 or 500 mg</td> <td>Every 6 hours</td> <td>3 hours</td> </tr> <tr> <td>6 to 20 mL/minute or intermittent HD or PD</td> <td>250 or 500 mg</td> <td>Every 12 hours</td> <td>3 hours</td> </tr> <tr> <td>CRRT<sup>¶</sup></td> <td>500 mg</td> <td>Every 6 hours</td> <td>3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td class="subtitle2_left_white" rowspan="5">Meropenem<sup>§</sup></td> <td>≥50 mL/minute</td> <td>1 or 2 g</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>25 to 49 mL/minute</td> <td>1 or 2 g</td> <td>Every 12 hours</td> <td>3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>10 to 24 mL/minute</td> <td>500 mg or 1 g</td> <td>Every 12 hours</td> <td>3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>&lt;10 mL/minute or intermittent HD</td> <td>500 mg or 1 g</td> <td>Every 24 hours, given after HD</td> <td>3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>CRRT<sup>¶</sup></td> <td>1 or 2 g</td> <td>Every 12 hours</td> <td>3 hours</td> </tr> <tr> <td class="subtitle2_left_white" rowspan="4">Ampicillin-sulbactam<sup>¥</sup></td> <td>≥30 mL/minute</td> <td>9 g</td> <td>Every 8 hours</td> <td>4 hours</td> </tr> <tr> <td>15 to 29 mL/min</td> <td>6 g</td> <td>Every 8 hours</td> <td>4 hours</td> </tr> <tr> <td>&lt;15 mL/min or intermittent HD</td> <td>6 g</td> <td>Every 12 hours</td> <td>4 hours</td> </tr> <tr> <td>CRRT<sup>¶</sup></td> <td>9 g</td> <td>Every 8 hours</td> <td>4 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td class="subtitle2_left_white" rowspan="6">Ceftazidime-avibactam<sup>‡</sup></td> <td>&gt;50 mL/minute</td> <td>2.5 g</td> <td>Every 8 hours</td> <td>2 to 3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>31 to 50 mL/minute</td> <td>1.25 g</td> <td>Every 8 hours</td> <td>2 to 3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>16 to 30 mL/minute</td> <td>0.94 g</td> <td>Every 12 hours</td> <td>2 to 3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>6 to 15 mL/minute</td> <td>0.94 g</td> <td>Every 24 hours</td> <td>2 to 3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>≤5 mL/minute or intermittent HD</td> <td>0.94 g</td> <td>Every 48 hours, given after HD</td> <td>2 to 3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>CRRT<sup>¶</sup></td> <td>1.25 g</td> <td>Every 8 hours</td> <td>2 to 3 hours</td> </tr> <tr> <td class="subtitle2_left_white" rowspan="5">Ceftolozane-tazobactam</td> <td>&gt;50 mL/minute</td> <td>3 g</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr> <td>30 to 50 mL/minute</td> <td>750 mg or 1.5 g</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr> <td>15 to 29 mL/minute</td> <td>375 or 750 mg</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr> <td>&lt;15 mL/minute or intermittent HD</td> <td>150 or 450 mg</td> <td>Every 8 hours (start after loading dose)</td> <td>3 hours</td> </tr> <tr> <td>CRRT<sup>¶</sup></td> <td>750 mg or 1.5 g</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td class="subtitle2_left_white" rowspan="6">Cefiderocol</td> <td>≥120 mL/min</td> <td>2 g</td> <td>Every 6 hours</td> <td>3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>60 to 119 mL/minute</td> <td>2 g</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>30 to 59 mL/minute</td> <td>1.5 g</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>15 to 29 mL/minute</td> <td>1 g</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>&lt;15 mL/minute or intermittent HD</td> <td>750 mg</td> <td>Every 12 hours</td> <td>3 hours</td> </tr> <tr class="highlight_lght_gray_text"> <td>CRRT<sup>¶</sup></td> <td>1.5 g</td> <td>Every 12 hours</td> <td>3 hours</td> </tr> <tr> <td class="subtitle2_left_white border_bottom_thick" rowspan="4">Aztreonam<sup>†</sup> (in combination with ceftazidime-avibactam)</td> <td>≥30 mL/min</td> <td>2 g</td> <td>Every 6 to 8 hours</td> <td>3 hours</td> </tr> <tr> <td>10 to 29 mL/min</td> <td>1 g</td> <td>Every 6 to 8 hours</td> <td>3 hours</td> </tr> <tr> <td>&lt;10 mL/min or intermittent HD</td> <td>2 g</td> <td>Every 24 hours</td> <td>3 hours</td> </tr> <tr class="border_bottom_thick"> <td>CRRT<sup>¶</sup></td> <td>2 g</td> <td>Every 12 hours</td> <td>3 hours</td> </tr> <tr> <td class="subtitle1_left"> </td> <td class="subtitle1_left">Estimated glomerular filtration rate</td> <td class="subtitle1_left">Dose</td> <td class="subtitle1_left">Dosing interval</td> <td class="subtitle1_left">Infusion time</td> </tr> <tr> <td class="subtitle2_left_white" rowspan="5">Meropenem-vaborbactam</td> <td>≥50 mL/minute</td> <td>4 g</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr> <td>30 to 49 mL/minute</td> <td>2 g</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> <tr> <td>15 to 29 mL/minute</td> <td>2 g</td> <td>Every 12 hours</td> <td>3 hours</td> </tr> <tr> <td>&lt;15 mL/minute or intermittent HD</td> <td>1 g</td> <td>Every 12 hours</td> <td>3 hours</td> </tr> <tr> <td>CRRT<sup>¶</sup></td> <td>2 g</td> <td>Every 8 hours</td> <td>3 hours</td> </tr> </tbody></table></div><div class="graphic_lgnd">The dosing recommendations reflect the opinion of UpToDate authors for adult patients with adequate intravenous access. The dosing strategies outlined may not be appropriate for all practice settings; they are based on pharmacodynamic models that use MIC distribution assumptions that may not match local patterns. Indications for use of extended infusions of beta-lactams are discussed in the dedicated topic on this issue. Separate calculators for estimation of creatinine clearance or glomerular filtration rate in conventional or International System of Units are available within UpToDate.</div><div class="graphic_footnotes"><p>CRRT: continuous renal replacement therapy; CVVHDF: continuous venovenous hemodiafiltration; HD: hemodialysis; MIC: minimum inhibitory concentration; PD: peritoneal dialysis.</p>
<p>* The higher dose of piperacillin-tazobactam (4.5 g) is used in certain situations, such as expected augmented drug clearance (as with critical illness or cystic fibrosis) or in cases of infections with pathogens that have high, but still susceptible, MICs to piperacillin-tazobactam when alternative agents are not appropriate. This higher dose can also be used for empiric treatment in communities or institutions where the <em>P. aeruginosa</em> MICs to piperacillin-tazobactam range higher than 32. Some studies have also used a dose of 4.5 g every 6 hours infused over 3 hours.</p>
<p>¶ The recommendations for CRRT dosing are based off of CVVHDF with a flow rate of 1 liter per hour and minimal residual renal function.</p>
<p>Δ Some studies have also used a 3-hour infusion time for cefepime.</p>
<p>◊ Imipenem is dosed by both weight and renal function. Dosing above is based on patient weight &gt;70 kg.</p>
<p>§ The higher dose of meropenem is used in patients with infections of the central nervous system or other life-threatening infections such as necrotizing fasciitis.</p>
<p>¥ High dosing of the sulbactam component with extended infusion times is recommended for carbapenem-resistant <em>Acinetobacter</em> infections<sup>[9]</sup>. Note that for patients with normal kidney function, an alternative dosing strategy is 27 g IV as a continuous infusion over 24 hours for patients with normal renal function.</p>
<p>‡ Some experts prefer a 3-hour extended infusion time (instead of standard 2 hours) for ceftazidime-avibactam for infections caused by carbapenem-resistant Enterobacterales, difficult-to-treat <em>P. aeruginosa</em>, and <em>S. maltophilia</em>.</p>
† Extended infusion aztreonam is preferred when used in combination with ceftazidime-avibactam for treatment of multidrug-resistant pathogens (eg, carbapenem-resistant Enterobacterales or <em>Stenotrophomonas</em>). In these cases, it is preferred that both agents are administered at the same time over 3 hours. Note the guideline panel suggests dosing aztreonam every 6 hours of aztreonam, but clinical data are lacking. Dosing every 8 hours is also reasonable and is logistically simpler, especially if clinical stability has been achieved<sup>[9-12]</sup>.</div><div class="graphic_reference">Data from:
<ol>
<li>Lodise TP, Lomaestro BM, Drusano GL, Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26:1320.</li>
<li>Bauer KA, West JE, O'Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 2013; 57:2907.</li>
<li>Hershberger E, Moukasassi MS, Steenbergen J, et al. CXA-101/Tazobactam (CXA/TAZ) probability of target attainment using population pharmacokinetic analysis. Presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases, Milan Italy May 2011.</li>
<li>Avycaz [Prescribing Information]. Cincinnati, OH: Forrest Pharmaceuticals, Inc.; 2015.</li>
<li>Hughes DW, Frei CR, Maxwell PR, et al. Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53:2014.</li>
<li>Cheatham SC, Shea KM, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents 2011; 37:46.</li>
<li>Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother 2010; 54:460.</li>
<li>Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther 2010; 32:766.</li>
<li>IDSA 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Infectious Diseases Society of America. Available at: https://www.idsociety.org/practice-guideline/amr-guidance/. (Accessed on July 13, 2023).</li>
<li>Lodise TP, Smith NM, O'Donnell N, et al. Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. J Antimicrob Chemother 2020; 75:2622.</li>
<li>Falcone M, Daikos GL, Tiseo G, et al. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales. Clin Infect Dis 2021; 72:1871.</li>
<li>Falcone M, Menichetti F, Cattaneo D, et al. Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. J Antimicrob Chemother 2021; 76:1025.</li>
</ol></div><div id="graphicVersion">Graphic 99434 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
